|
    CODX U.S.: Nasdaq

    Co-Diagnostics Inc.

    CODXUS
    After Hours
    Back To Top
    Last Updated: Mar 23, 2020 4:22 p.m. EDT Delayed quote

    $ 9.60

    0.14 1.48%
    After Hours Volume: 7.7K
    Health Care/Life Sciences 0.03%
    Close Chg Chg %
    $9.46 -0.99 -9.47% -0.99 -9.47%
    Advanced Charting
    • $
    • %
    • Vol
    Advanced Charting
    39.36% vs Avg.
    Volume: 4.3M 65 Day Avg. - 10.9M
    Open: 9.99
    Close: 9.46
    9.00 Day Low/High 9.99
    Day Range
    0.69 52 Week Low/High 21.75

    Your Watchlist

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    7073彩票注册Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    Key Data

    • Open $9.99
    • Day Range 9.00 - 9.99
    • 52 Week Range 0.69 - 21.75
    • Market Cap $265.28M
    • Shares Outstanding 25.39M
    • Public Float 18.74M
    • Beta -0.35
    • Rev. per Employee $1.86K
    • P/E Ratio n/a
    • EPS $-0.42
    • Yield n/a
    • Dividend n/a
    • Ex-Dividend Date n/a
    • Short Interest 2.46M 02/28/20
    • % of Float Shorted 13.11%
    • Average Volume 10.94M

    Performance

    5 Day
    • 4.07%
    1 Month
    • 140.71%
    3 Month
    • 880.21%
    YTD
    • 956.75%
    1 Year
    • 694.96%

    Recent News

    • MarketWatch
    • WSJ
    Read full story

    A watershed moment is on the way if stocks can’t hold this level

    More Companies Are Offering Coronavirus Tests. Don’t Expect Stock Bumps.

    7073彩票注册Even if three million Americans get tested, the U.S. market is unlikely to be a big business.

    Read full story

    ‘Head-fake’ stock market rally may become real with interest-rate cuts

    Co-Diagnostics' stock tumbles after Maxim downgrades following massive run up in price

    Shares of Co-Diagnostics Inc. tumbled 14% in premarket trading Tuesday, to pull back from the previous session's record close, after Maxim Group analyst Jason McCarthy downgraded the molecular diagnostics company citing concerns over valuation after the recent rocket ride up. The stock closed Monday at $17.81, a near 16-fold increase from the Jan. 22 closing price of $1.13, compared with a 7.0% drop in the S&P 500 over the same time. The stock's rally started after the company said it had completed principle design work for a screening test for the COVID-19. McCarthy said he believes there is a "significant opportunity" for the company's COVID-19 test, but Co-Diagnostics' market capitalization has climbed more than $450 million from about $20 million in just a few weeks, "which in our opinion takes into account the potential of its COVID-19 test." While fundamentals are sound for the company, McCarthy said he was "stepping aside" based on valuation.

    Co-Diagnostics downgraded to hold from buy at Maxim Group

    Read full story

    FDA to now allow more labs to immediately begin testing for coronavirus

    Co-Diagnostics stock soars 57% on high hopes for its coronavirus test

    Shares of Co-Diagnostics Inc. , a molecular diagnostics company that has developed a test for the coronavirus, rose another 57% on Thursday, bringing its month-to-date gains to 333%, after the company said it has received a CE Mark for its test. A CE Mark, or certification mark, indicates the test is compliant with health and safety standards that allow it to be sold in the European Economic Area. The stock has been on a tear ever since it came up with the test which it is selling for research use. The virus, which broke out in Wuhan, China last year, has sickened more than 80,000 people around the world. Thursday's gains came even after Co-Diagnostics said it has completed a $4.2 million registered direct offering priced at-the-market. The company has been taking advantage of the virus-driven rally in its stock to issue new shares, although the stock typically falls when it does dilutive financings. Maxim analyst Jason McCarthy said Wednesday Co-Diagostic's test is easier to use than the test in use by the Centers for Disease Control and Prevention. Maxim rates the stock a buy, even after it has gained 1,401% in the year to date. The S&P 500 has fallen 6% in the same time frame.

    The Stock of the Coronavirus-Test Developer Can Keep Rising, Analyst Says

    7073彩票注册Maxim Group analyst Jason McCarthy rates Co-Diagnostics a Buy. He raised his price target to $5 from $2 on Tuesday. The stock closed at $3.32 on Friday.

    Read full story

    Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine

    Read full story

    Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries

    Read full story

    Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports

    Read full story

    Dow ends more than 450 points lower as spread of coronavirus quashes buying sentiment

    Read full story

    CDC officials say coronavirus is similar to SARS, no new U.S. cases reported

    Vaccine, diagnostics stocks rise again on spreading coronavirus

    Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc. , up 42%; NanoViricides Inc. , up 29%; Allied Healthcare Products Inc. , up 22%; Inovio Pharmaceuticals Inc. , up 24%; and Novavax Inc. , up 13%. The Centers for Disease Control and Prevention said Sunday that there are now five confirmed cases in the U.S., all of whom had traveled to Wuhan, the city in China where the virus was first identified. Chinese health officials have said that more than 2,700 people have been sickened and at least 80 people died, according to The Wall Street Journal. Market concerns have sent global stocks and U.S. futures tumbling on Monday. The S&P 500 and the Dow Jones Industrial Average are both 1% over the last week.

    Read full story

    Second coronavirus patient identified, extent and duration of airport screening to be ‘re-evaluated’

    Co-Diagnostics' stock tumbles after stock sale agreement priced at 29% discount

    7073彩票注册Shares of Co-Diagnostics Inc. tumbled 16% in premarket trading Friday, after the molecular diagnostics company took advantage of the prior session's big rally to enter into a stock sale agreement. The company said it agreed to sell 3,448,278 shares, representing about 20% of the shares outstanding, to institutional investors at $1.45 a share, which was 28.6% below Thursday's closing price of $2.03 but 28.3% above Wednesday's closing price of $1.13. Co-Diagnostics's stock had rocketed 80% on Thursday on trading volume of 36.1 million shares, after the company said it had "completed principle design work" for a test to screen the Wuhan coronavirus. The stock has nearly doubled (up 99%) over the past three months through Thursday, while the S&P 500 has gained 10.5%.

    Read full story

    Inovio’s stock soars after receiving grant to develop coronavirus vaccine

    Co-Diagnostics stock nearly triples after completion of design work for coronavirus screener

    Shares of Co-Diagnostics Inc. nearly tripled (up 177%) on heavy volume in premarket trading Thursday, after the molecular diagnostics company said it had completed principle design work for a polymerase chain reaction (PCR) screening test for new coronavirus. Trading volume soared to 1.9 million shares, enough to make the stock the most actively traded before the open, and already more than 10-times the full-day average of about 161,000 shares. The company said its new test features its CoPrimer technology. "One of the most important advantages of our CoPrimer platform is its ability to reliably and accurately differentiate between similar genetic sequences, in order to reduce the likelihood of a false positive diagnosis," said Chief Executive Dwight Egan. "We believe that if the [World Health Organization] takes the step of declaring the illness a global health emergency following collection of more data in the days and weeks to come, Co-Diagnostics will be well positioned to quickly assist in providing these state of the art tools to affected countries." The stock has gained 9.7% over the past 12 months through Wednesday, while the S&P 500 has advanced 25.9%.

    7073彩票注册Testing for the new coronavirus could ramp up fast after the FDA said it would speed approval of tests from hospital and public-health laboratories to augment the limited supply from the federal government.

    on The Wall Street Journal

    Recent News

    • Other News
    • Press Releases

    7073彩票注册Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.

    on Zacks.com

    H.C.[...]

    on SmarterAnalyst

    7 7073彩票注册 to Buy That Have Survived the Recent Carnage

    on InvestorPlace.com

    7073彩票注册Is (CODX) Outperforming Other Medical 7073彩票注册 This Year?

    on Zacks.com

    7073彩票注册RDS.A, NRZ among premarket gainers

    on Seeking Alpha

    Amidst the deadly coronavirus outbreak, Wall Street suffered its biggest point drop in a single day ...

    on Baystreet.ca

    7073彩票注册Co-Diagnostics JV CoSara receives license for COVID-19 diagnostic; shares up 12% premarket

    on Seeking Alpha

    7073彩票注册In a report released today, Yi Chen from H.C.[...]

    on SmarterAnalyst

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals

    on Zacks.com

    DOW, REGN among premarket gainers

    on Seeking Alpha

    There Doesn't Appear To Be Any Real Interest In Co-Diagnostics' Coronavirus Test - We Reiterate Our $1 Price Target

    on Seeking Alpha

    7073彩票注册FDA to allow states to authorize coronavirus tests

    on Seeking Alpha

    7073彩票注册We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.

    on Zacks.com

    The Zacks Analyst Blog Highlights: Netflix, Microsoft, Sempra Energy, Co-Diagnostics and Moderna

    on Zacks.com

    Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 16th.

    on Zacks.com

    Coronavirus plays on the move premarket

    on Seeking Alpha

    Coronavirus plays up premarket as Rome burns

    on Seeking Alpha

    7073彩票注册The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities

    on GuruFocus.com

    The Coronavirus has now been declared a pandemic by the World Health Organization (WHO). Entire countries ...

    on Baystreet.ca

    Even though majority of investors are in a state of shock, many know how to profit during uncertain times like these. Here're five ways you can put your money to work amid the coronavirus outbreak.

    on Zacks.com

    PreCheck Begins Filling Orders for Coronavirus (COVID-19) PCR Test and Announces Distribution Agreements in Romania and Moldova

    PreCheck Begins Filling Orders for Coronavirus (COVID-19) PCR Test and Announces Distribution Agreements in Romania and Moldova

    on GlobeNewswire

    PreCheck Begins Filling Orders for Coronavirus (COVID-19) PCR Test and Announces Distribution Agreements in Romania and Moldova

    7073彩票注册PreCheck Begins Filling Orders for Coronavirus (COVID-19) PCR Test and Announces Distribution Agreements in Romania and Moldova

    on GlobeNewswire

    Co-Diagnostics, Inc Completes Successful Clinical Evaluation Required for FDA Emergency Use Authorization

    Co-Diagnostics, Inc Completes Successful Clinical Evaluation Required for FDA Emergency Use Authorization

    on BusinessWire - BZX

    Trump's Gains Nearly All Lost as the Market Reacts to COVID-19

    Trump's Gains Nearly All Lost as the Market Reacts to COVID-19

    on Baystreet.ca

    Co-Diagnostics JV CoSara First Indian Company to Receive License for COVID-19 Diagnostic

    Co-Diagnostics JV CoSara First Indian Company to Receive License for COVID-19 Diagnostic

    on BusinessWire - BZX

    Recent Government Policies Aim to Stimulate the Market Recovery

    Recent Government Policies Aim to Stimulate the Market Recovery

    on PR Newswire - PRF

    FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test

    FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test

    on BusinessWire - BZX

    PreCheck Health Announces 3rd Coronavirus COVID-19 PCR Test Distribution Agreement

    PreCheck Health Announces 3rd Coronavirus COVID-19 PCR Test Distribution Agreement

    on BusinessWire - BZX

    Global Markets Are In Turmoil Sending Investors Scrambling For A Safe Haven

    Global Markets Are In Turmoil Sending Investors Scrambling For A Safe Haven

    on Baystreet.ca

    PreCheck Health to Exclusively Distribute Coronavirus COVID-19 Test in Ecuador, a Population of 16 Million, for Co-Diagnostics, Inc.

    PreCheck Health to Exclusively Distribute Coronavirus COVID-19 Test in Ecuador, a Population of 16 Million, for Co-Diagnostics, Inc.

    on BusinessWire - BZX

    Global Response to the COVID-19 Outbreak Intensifies

    Global Response to the COVID-19 Outbreak Intensifies

    on PR Newswire - PRF

    Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.

    7073彩票注册Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.

    on BusinessWire - BZX

    Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target

    7073彩票注册Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target

    on GlobeNewswire

    Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target

    7073彩票注册Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target

    on GlobeNewswire

    H.C. Wainwright Reiterates Buy on Co-Diagnostics (NASDAQ:CODX) with a $20 PT as Shipments to U.S and Overseas Markets Continue

    H.C. Wainwright Reiterates Buy on Co-Diagnostics (NASDAQ:CODX) with a $20 PT as Shipments to U.S and Overseas Markets Continue

    on GlobeNewswire

    H.C. Wainwright Reiterates Buy on Co-Diagnostics (NASDAQ:CODX) with a $20 PT as Shipments to U.S and Overseas Markets Continue

    H.C. Wainwright Reiterates Buy on Co-Diagnostics (NASDAQ:CODX) with a $20 PT as Shipments to U.S and Overseas Markets Continue

    on GlobeNewswire

    Co-Diagnostics Rallies On coronavirus Testing Opportunity

    7073彩票注册Co-Diagnostics Rallies On coronavirus Testing Opportunity

    on Stock Market Press

    Co-Diagnostics (NASDAQ:CODX) Ready to Meet U.S Vice President's Plea for More Domestic Tests

    Co-Diagnostics (NASDAQ:CODX) Ready to Meet U.S Vice President's Plea for More Domestic Tests

    on GlobeNewswire

    Co-Diagnostics (NASDAQ:CODX) Ready to Meet U.S Vice President's Plea for More Domestic Tests

    Co-Diagnostics (NASDAQ:CODX) Ready to Meet U.S Vice President's Plea for More Domestic Tests

    on GlobeNewswire

    Researchers Race to Advance Viral Disease Identification as COVID-19 Spreads

    Researchers Race to Advance Viral Disease Identification as COVID-19 Spreads

    on PR Newswire - PRF

    Co-Diagnostics Inc.

    Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT. (See Full Profile)

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings
    689彩票邀请码 7072彩票开户 7073彩票注册 963彩票开户 7073彩票网址 7073彩票地址 7073彩票登录 66顺彩票app 8炫彩彩票app 677彩票开户